

## INTERNAL VETERANS AFFAIRS USE HEMATOLOGIC AND LYMPHATIC CONDITIONS, INCLUDING LEUKEMIA DISABILITY BENEFITS QUESTIONNAIRE

**IMPORTANT -** THE DEPARTMENT OF VETERANS AFFAIRS (VA) *WILL NOT PAY* OR *REIMBURSE* ANY EXPENSES OR COST INCURRED IN THE PROCESS OF COMPLETING AND/OR SUBMITTING THIS FORM. PLEASE READ THE PRIVACY ACT AND RESPONDENT BURDEN INFORMATION ON REVERSE BEFORE COMPLETING FORM.

REVERSE BEFORE COMPLETING FORM.							
NAME OF PATIENT/VETERAN	PATIENT/VETERAN'S SOCIAL SECURITY NUMBER						
NOTE TO PHYSICIAN - Your patient is applying to the U.S. Department of Veterans Affairs (VA) for disability benefits. VA will consider the information you provide on this questionnaire as part of their evaluation in processing the Veteran's claim.							
IS THIS DBQ BEING COMPLETED IN CONJUNCTION WITH A VA21-2507, C&P EXAMINATION REQUEST?							
YES NO							
If no, how was the examination completed (check all that apply)?							
In-person examination							
Records reviewed							
Other, please specify:							
Comments:							
ACCEPTABLE CLINICAL EVIDENCE (ACE)							
INDICATE METHOD USED TO OBTAIN MEDICAL INFORMATION TO COMPLETE THIS DOCUMENT:  Review of available records (without in-person or video telehealth examination) using the Acceptable Clinical E	evidence (ACE) process because the existing medical						
evidence provided sufficient information on which to prepare the DBQ and such an examination will likely provi	de no additional relevant evidence.						
Review of available records in conjunction with a telephone interview with the Veteran (without in-person or tele existing medical evidence supplemented with a telephone interview provided sufficient information on which to provide no additional relevant evidence.							
Examination via approved video telehealth							
In-person examination							
EVIDENCE REVIEW							
EVIDENCE REVIEWED (check all that apply):							
Not requested No records were reviewed							
VA claims file (hard copy paper C-file)							
U VA e-folder □ variation   VA e-folder □ v							
CPRS							
Other (please identify other evidence reviewed):							
EVIDENCE COMMENTS:							

## **SECTION I - DIAGNOSIS** NOTE: These are the condition(s) for which an evaluation has been requested on an exam request form (Internal VA) or for which the Veteran has requested medical evidence be provided for submission to VA. 1A. CHECK THE CLAIMED HEMATOLOGICAL AND/OR LYMPHATIC CONDITION(S) THAT PERTAIN TO THIS DBQ: NOTE: These are the diagnoses determined during this current evaluation of the claimed condition(s) listed above. If there is no diagnosis, if the diagnosis is different from a previous diagnosis for this condition, or if there is a diagnosis of a complication due to the claimed condition, explain your findings and reasons in the comments section. Date of diagnosis can be the date of evaluation if the clinician is making the initial diagnosis, or an approximate date determined through record review or reported history. ICD CODE: DATE OF DIAGNOSIS: Agranulocytosis, acquired Leukemia Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_\_\_ Chronic lymphocytic leukemia (CLL) ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_ Hairy cell or other B-cell leukemia ICD CODE: DATE OF DIAGNOSIS: Other ICD CODE: DATE OF DIAGNOSIS: ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_\_\_ Hodgkin's lymphoma Active disease Treatment phase DATE OF DIAGNOSIS: Non-Hodgkin's lymphoma Active disease Treatment phase Indolent and non-contiguous phase of low grade NHL Multiple myeloma ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_\_\_ Myelodysplastic syndrome ICD CODE: DATE OF DIAGNOSIS: Solitary plasmacytoma ICD CODE: DATE OF DIAGNOSIS: Anemia Aplastic anemia ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_\_\_ Iron deficiency anemia ICD CODE: DATE OF DIAGNOSIS: Folic acid deficiency ICD CODE: DATE OF DIAGNOSIS: Pernicious anemia or other Vitamin B12 deficiency anemia ICD CODE: DATE OF DIAGNOSIS: Acquired hemolytic anemia ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_ ICD CODE: DATE OF DIAGNOSIS: Other \_ AL amyloidosis (primary amyloidosis) \_\_ DATE OF DIAGNOSIS: Immune thrombocytopenia ICD CODE: DATE OF DIAGNOSIS: Polycythemia vera ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_\_\_ Sickle cell anemia ICD CODE: DATE OF DIAGNOSIS: ICD CODE: DATE OF DIAGNOSIS: Splenectomy Are there complications **such as** systemic infections with encapsulated bacteria? YES NO (If Yes, complete SECTION VIII - OTHER PERTINENT PHYSICAL FINDINGS, COMPLICATIONS, CONDITIONS, SIGNS AND/OR SYMPTOMS). ICD CODE: (If checked, complete SECTION VIII - OTHER PERTINENT PHYSICAL FINDINGS, COMPLICATIONS, CONDITIONS, SIGNS AND/OR SYMPTOMS).

1B. IF THERE ARE ADDITIONAL OR PRIOR DIAGNOSES THAT PERTAIN TO HEMATOLOGIC OR LYMPHATIC CONDITIONS, LIST USING ABOVE FORMAT:

ICD CODE:

ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_

Other diagnosis #2: \_\_\_\_\_\_ ICD CODE: \_\_\_\_\_ DATE OF DIAGNOSIS: \_\_\_\_\_

Adenitis, tuberculous (Also complete the Infectious Diseases (Other Than ICD CODE:

HIV-Related Illness, Chronic Fatigue Syndrome, or Tuberculosis) Disability

Essential thrombocythemia or primary myelofibrosis

Benefits Questionnaire).

Other diagnosis #1:

Other diagnosis #3:

Other, specify

DATE OF DIAGNOSIS:

DATE OF DIAGNOSIS:

SECTION II - MEDICAL HISTORY					
2A. DESCRIBE THE HISTORY (including cause (if known), onset and course) OF THE VETERAN'S CURRENT HEMATOLOGIC OR LYMPHATIC CONDITION(S) (brief summary):					
2B. IS CONTINUOUS MEDICATION REQUIRED FOR CONTROL OF A HEMATOLOGIC OR LYMPHATIC CONDITION, INCLUDING ANEMIA OR THROMBOCYTOPENIA CAUSED BY TREATMENT FOR A HEMATOLOGIC OR LYMPHATIC CONDITION?					
YES NO					
IF YES, LIST ONLY THOSE MEDICATIONS REQUIRED FOR CONTROL OF THE VETERAN'S HEMATOLOGIC OR LYMPHATIC CONDITION, INCLUDING ANEMIA OR THROMBOCYTOPENIA CAUSED BY TREATMENT FOR A HEMATOLOGIC OR LYMPHATIC CONDITION. PROVIDE THE NAME OF THE MEDICATION AND THE CONDITION THE MEDICATION IS USED TO TREAT:					
2C. INDICATE THE STATUS OF THE PRIMARY HEMATOLOGIC OR LYMPHATIC CONDITION:  ACTIVE REMISSION NOT APPLICABLE					
SECTION III - TREATMENT					
3A. HAS THE VETERAN COMPLETED ANY TREATMENT OR IS THE VETERAN CURRENTLY UNDERGOING ANY TREATMENT FOR ANY HEMATOLOGIC OR LYMPHATIC CONDITION, INCLUDING LEUKEMIA?					
YES NO; WATCHFUL WAITING					
IF YES, INDICATE TYPE OF TREATMENT THE VETERAN IS CURRENTLY UNDERGOING OR HAS COMPLETED (Check all that apply):					
Treatment completed; currently in watchful waiting status					
☐ Transplant (specify type)					
Peripheral blood stem cell transplant Bone marrow stem cell transplant					
Other (specify)					
If checked, provide:  Date of hospital admission and location:					
Date of hospital discharge after transplant:					
Surgery, if checked describe:  Date(s) of surgery:					
Radiation therapy					
Date of most recent treatment:					
Date of completion of treatment or anticipated date of completion:					
Antineoplastic chemotherapy					
Date of most recent treatment:					
Date of completion of treatment or anticipated date of completion:					
Other therapeutic procedure					
If checked, describe procedure:					
Date of most recent procedure:					
Other therapeutic treatment					
If checked, describe treatment:					
Date of completion of treatment or anticipated date of completion:					
SECTION IV - ANEMIA AND THROMBOCYTOPENIA					
4A. DOES THE VETERAN HAVE ANEMIA OR THROMBOCYTOPENIA, INCLUDING THAT CAUSED BY TREATMENT FOR A HEMATOLOGIC OR LYMPHATIC CONDITION?					
☐ YES ☐ NO					
IF YES, COMPLETE THE FOLLOWING:					

SECTION IV - ANEMIA AND THROMBOCYTOPENIA (Continued)					
4B. DOES THE VETERAN HAVE ANEMIA (other than Sickle Cell Anemia) OR THROMBOCYTOPENIA?  YES NO IF YES, PLEASE CHECK TYPE:					
Aplastic anemia (complete 4C)  Iron deficiency anemia (complete 4D)					
Folic acid deficiency (complete 4E)  Pernicious anemia or other Vitamin B12 deficiency anemia (complete 4F)  Acquired hemolytic anemia (complete 4G)					
Immune thrombocytopenia (complete 4H)  Other, specify					
IS THE ANEMIA CAUSED BY TREATMENT FOR ANOTHER HEMATOLOGIC OR LYMPHATIC CONDITION?  YES NO  IF YES, PROVIDE THE NAME OF THE OTHER HEMATOLOGIC OR LYMPHATIC CONDITION CAUSING THE SECONDARY ANEMIA:					
4C. APLASTIC ANEMIA:					
Requiring peripheral blood stem cell transplant Requiring bone marrow stem cell transplant Requiring transfusion of platelets, on average, at least: once every six weeks per 12-month period once every three months per 12-month period					
once per 12-month period  Requiring transfusion of red cells, on average, at least:  once every six weeks per 12-month period					
once every three months per 12-month period once per 12-month period					
☐ Infections recurring, on average, at least: ☐ once every six weeks per 12-month period ☐ once every three months per 12-month period ☐ once per 12-month period					
Using continuous therapy with immunosuppressive agent Using continuous therapy with newer platelet stimulating factors  NOTE: The term "newer platelet stimulating factors" includes medication, factors, or other agents approved by the United States Food and Drug Administration.					
4D. IRON DEFICIENCY ANEMIA					
Requiring intravenous iron infusions 4 or more times per 12-month period Requiring intravenous iron infusions at least 1 time but less than 4 times per 12-month period Requiring continuous treatment with oral supplementation Requiring treatment only by dietary modification Asymptomatic					
4E. FOLIC ACID DEFICIENCY  Requiring continuous treatment with high-dose oral supplementation Requiring treatment only by dietary modification Asymptomatic					

SECTION IV - ANEMIA AND THROM	MBOCYTOPENIA (Continued)				
4F. PERNICIOUS ANEMIA OR OTHER VITAMIN B12 DEFICIENCY ANEMIA					
For initial diagnosis requiring transfusion due to severe anemia					
If checked, provide the date of initial diagnosis requiring transfusion	and				
the date of hospital discharge or cessation of parenteral B12 therapy					
Signs or symptoms related to central nervous system impairment, such as encephalor	pathy, myelopathy, or severe peripheral neuropathy, requiring parenteral B12				
therapy					
Requiring continuous treatment with Vitamin B12 injections					
Requiring continuous treatment with Vitamin B12 sublingual tablets					
Requiring continuous treatment with high-dose oral tablets					
Requiring continuous treatment with Vitamin B12 nasal spray or gel					
NOTE: If there are any residual effects of pernicious anemia, such as neurologic involve gastrointestinal residuals, ALSO complete appropriate Questionnaire for each condition.	ment causing peripheral neuropathy, myelopathy, dementia, or related				
4G. ACQUIRED HEMOLYTIC ANEMIA					
Required a bone marrow transplant					
Requiring continuous intravenous or immunosuppressive therapy (e.g., prednisone, C	cytoxan, azathioprine, or rituximab)				
Requiring immunosuppressive medication 4 or more times per 12-month period					
Requiring 2-3 courses of immunosuppressive therapy per 12-month period					
Requiring one course of immunosuppressive therapy per 12-month period					
Asymptomatic					
4H. IMMUNE THROMBOCYTOPENIA					
Requiring chemotherapy for chronic refractory thrombocytopenia					
Requiring immunosuppressive therapy					
Platelet count 30,000 or below despite treatment Platelet count higher than 30,000 but not higher than 50,000 with history of hospitalization because of severe bleeding requiring intravenous immune globulin, high dose					
parenteral corticosteroids, and platelet transfusions	and blooding which requires and particularity thereon as introvenue increases				
Platelet count higher than 30,000 but not higher than 50,000 with mild mucous membra globulin	arie bieeding which requires oral contcosteroid therapy or intraverious immune				
Platelet count higher than 30,000 but not higher than 50,000 with immune thrombocytons.	openia which requires oral corticosteroid therapy or intravenous immune globulin				
Platelet count higher than 30,000 but not higher than 50,000, not requiring treatment	1, 1, 3				
Platelet count above 50,000 and asymptomatic					
In remission					
SECTION V - LEUKEMIA, MULTIPLE MYELOMA, AGRANULOCYTOS MYELOFIBROSIS, AND MYELOD					
5A. DOES THE VETERAN HAVE LEUKEMIA, MULTIPLE MYELOMA, AGRANULOCYTOSI MYELOFIBROSIS, OR MYELODYSPLASTIC SYNDROMES?	IS, ACQUIRED, ESSENTIAL THROMBOCYTHEMIA, PRIMARY				
YES NO					
IF YES, PLEASE CHECK TYPE:					
Chronic lymphocytic leukemia (complete 5B)					
Monoclonal B-cell lymphocytosis (MBL) (complete 5B)					
Hairy cell or other B-cell leukemia (complete 5B)					
Chronic myelogenous leukemia (complete 5B)					
Chronic myeloid leukemia (complete 5B)					
Chronic granulocytic leukemia (complete 5B)					
Multiple myeloma (complete 5C)  Agranulocytosis, acquired (complete 5D)					
Essential thrombocythemia or primary myelofibrosis (complete 5E)					
Myelodysplastic syndromes (complete 5F)					
Other, specify					

SECTION V - LEUKEMIA, MULTIPLE MYELOMA, AGRANULOCYTOSIS, ACQUIRED, ESSENTIAL THROMBOCYTHEMIA, PRIMARY MYELOFIBROSIS, AND MYELODYSPLASTIC SYNDROMES (Continued)
5B. WHAT IS THE STATUS OF LEUKEMIA?
ACTIVE REMISSION
Annual Control of the
Asymptomatic, Rai Stage 0
Requiring peripheral blood stem cell transplant  Requiring bone marrow stem cell transplant
Requiring continuous myelosuppressive therapy
Requiring continuous imperosuppressive therapy  Requiring continuous immunosuppressive therapy treatment
Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy
with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission
In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors
5C. WHAT IS THE STATUS OF MULTIPLE MYELOMA?
Symptomatic (if checked, provide date of the diagnosis of symptomatic multiple myeloma)
Asymptomatic
Smoldering or monoclonal gammopathy of undetermined significance (MGUS)
NOTE: Current validated biomakers of symptomatic multiple myeloma, asymptomatic, smoldering or monoclonal gammopathy of undetermined significance (MGUS)
are acceptable for the diagnosis of multiple myeloma as defined by the American Society of Hematology (ASH) and International Myeloma Working Group (IMWG).
5D. WHAT IS THE STATUS OF AGRANULOCYTOSIS, ACQUIRED?
Requiring bone marrow transplant
Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF))
Requiring continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (μl) but less than 1000/μl
Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl
Requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl
Infections recurring, on average, at least once every six weeks per 12-month period
Infections recurring, on average, at least once every three months per 12-month period
Infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period
Requiring continuous medication (e.g., antibiotics) for control
5E. WHAT IS THE STATUS OF ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS?
Requiring continuous myelosuppressive therapy
Requiring intermittent myelosuppressive therapy
Requiring peripheral blood stem cell transplant
Requiring bone marrow stem cell transplant
Requiring chemotherapy
Requiring interferon treatment
Requiring interferon treatment to maintain platelet count < 500 x 10 <sup>9</sup> /L
Requiring interferon treatment to maintain platelet count of 200,000-400,000
Requiring interferon treatment to maintain white blood cell (WBC) count of 4,000-10,000
Asymptomatic
5F. WHAT IS THE STATUS OF MYELODYSPLASTIC SYNDROMES?
Requiring peripheral blood stem cell transplant
Requiring bone marrow stem cell transplant
Requiring chemotherapy
Requiring 4 or more blood or platelet transfusions per 12-month period
Requiring 1 to 3 blood or platelet transfusions per 12-month period
Infections requiring hospitalization 3 or more times per 12-month period
Infections requiring hospitalization 1 to 2 times per 12-month period
Requiring biologic therapy on an ongoing basis
Requiring erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period

SECTION VI - POLYCYTHEMIA VERA
6A. DOES THE VETERAN HAVE POLYCYTHEMIA VERA?  YES NO  IF YES, CHECK ALL THAT APPLY:
Requiring peripheral blood or bone marrow stem-cell transplant for the purpose of ameliorating the symptom burden Requiring chemotherapy (including myelosuppressants) for the purpose of ameliorating the symptom burden Requiring phlebotomy 6 or more times per 12-month period or molecularly targeted therapy for the purpose of controlling RBC count
Requiring phlebotomy 4-5 times per 12-month period to maintain platelets < 200,000 or white blood cells (WBC) < 12,000  Requiring phlebotomy 3 or fewer times per 12-month period to maintain all blood values at reference range levels
Requiring continuous biologic therapy or myelosuppresive agents, to include interferon, to maintain platelets < 200,000 or white blood cells (WBC) < 12,000
Requiring biologic therapy or interferon on an intermittent basis as needed to maintain all blood values at reference range levels  Other, describe:
NOTE: If there are complications due to polycythemia vera such as hypertension, gout, stroke or thrombotic disease, ALSO complete appropriate Questionnaire for each condition.
SECTION VII - SICKLE CELL ANEMIA
7A. DOES THE VETERAN HAVE SICKLE CELL ANEMIA?  YES NO
IF YES, CHECK ALL THAT APPLY:  Symptoms preclude even light manual labor
Symptoms preclude other than light manual labor
With anemia, thrombosis, and infarction
With at least 4 or more painful episodes per 12-month period, occurring in skin, joints, bones, or any major organs caused by hemolysis and sickling of red blood cells  With 3 painful episodes per 12-month period
With 1 or 2 painful episodes per 12-month period  With 1 or 2 painful episodes per 12-month period
☐ With identifiable organ impairment
In remission
Asymptomatic
Other, describe:
SECTION VIII - OTHER PERTINENT PHYSICAL FINDINGS, COMPLICATIONS, CONDITIONS, SIGNS AND/OR SYMPTOMS
8A. DOES THE VETERAN HAVE ANY OTHER PERTINENT PHYSICAL FINDINGS, COMPLICATIONS, CONDITIONS, SIGNS AND/OR SYMPTOMS RELATED TO THE CONDITIONS LISTED IN THE DIAGNOSIS SECTION ABOVE?  YES NO
IF YES, DESCRIBE (brief summary):
(Also if indicated, complete the appropriate questionnaire for each condition)
8B. DOES THE VETERAN HAVE ANY SCARS OR OTHER DISFIGUREMENT (of the skin) RELATED TO ANY CONDITIONS OR TO THE TREATMENT OF ANY CONDITIONS LISTED IN THE DIAGNOSIS SECTION?  YES NO
(IF YES, ALSO COMPLETE APPROPRIATE DERMATOLOGICAL DBQ)

	SE	CTION IX - DIAGNOSTIC TESTING						
NOTE: If testing has been performed and reflects Veteran's current condition, no further testing is required. When appropriate, provide most recent complete blood count.								
9A. HAS LABORATORY TESTING BEEN PERFO YES NO IF YES, PROVIDE RESULTS:	RMED?							
Hemoglobin (gm/100ml):		Date:						
Hematocrit:		Date:						
Red blood cell (RBC) count:		Date:						
White blood cell (WBC) count:		Date:						
White blood cell differential count:		Date:						
Platelet count:		Date:						
9B. ARE THERE ANY OTHER SIGNIFICANT DIAGE YES NO IF YES, PROVIDE TYPE OF TEST OR PROCEDU								
		CTION X - FUNCTIONAL IMPACT						
10. DOES THE VETERAN'S HEMATOLOGIC OR YES NO (IF YES, DESCRIBE IMPACT OF EACH OF THE		ATOLOGIC AND/OR LYMPHATIC CONDIT		MORE EXAMPLES):				
44 PEMARKO (III.)		SECTION XI - REMARKS						
11. REMARKS (If any):								
		HYSICIAN'S CERTIFICATION AND SI						
CERTIFICATION - To the best of my kn 12A. PHYSICIAN'S SIGNATURE	owledge, the in	formation contained herein is accurate 12B. PHYSICIAN'S PRINTED NAME	, complete and current.	12C. DATE SIGNED				
IZA. PRISICIAN S SIGNATURE		126. PHYSICIANS PRINTED NAME		120. DATE SIGNED				
12D. PHYSICIAN'S PHONE AND FAX NUMBER	12E. NATIONAL PROVIDER IDENTIFIER (NPI) NUMBER 12F. MEDICAL LICENSE			L NUMBER AND STATE				
12G. PHYSICIAN'S ADDRESS								